Browsing: Exelixis

Adam GaultOppenheimer has downgraded Exelixis (NASDAQ:EXEL) to perform from outperform, citing concerns about differentiation between the company’s drugs zanzalintinib and…

Exelixis (NASDAQ:EXEL) expects $2.165B (consensus estimate: $2.17B) in total revenues for fiscal year 2024, with around ~$1.805B in net product…

peterschreiber.mediaBrookline Capital Markets initiated coverage of Exelixis (NASDAQ:EXEL) with a buy rating, highlighting the company’s revenue potential. The investment firm…

peterschreiber.media BMO Capital Markets has downgraded Exelixis (NASDAQ:EXEL) to market perform from outperform as it sees limited upside for the…

Bet_Noire BofA has downgraded Exelixis (NASDAQ:EXEL) to neutral from buy, commenting that it sees a more balanced risk/reward following the…